Document Detail


The route of administration (oral vs intravenous) does not influence dose or outcome in Graves' disease and unifocal autonomy.
MedLine Citation:
PMID:  15759147     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: In a prospective randomised study, we investigated the influence of the route of administration of radioiodide on dosimetry and therapy outcome. METHODS: Fifty-four patients suffering from Graves' disease (GD) and 60 patients with unifocal autonomy (UA) participated in the study and were randomly treated with either orally or intravenously administered radioiodide. Pretherapeutic dosimetry was based on single uptake measurements with a calibrated uptake probe system. The radioiodine kinetics during hospitalisation was assessed by daily bedside uptake measurements. Therapeutic dose was determined by half-life and thyroid uptake at the time of discharge using the same uptake probe as for the radioiodine test. RESULTS: No improvement in accuracy of dosimetry was achieved when radioiodide was administered intravenously. Mean therapeutic doses were identical following intravenous or oral administration. Variation in the achieved dose was slightly higher in the patients receiving oral administration, this being attributable to larger deviations in discrete activities of the capsules administered as compared with the values determined by dosimetry. No differences according to treatment modality were found with regard to therapeutic outcome. Eighty-seven patients attended 6-month follow-up after therapy. In the UA group, successful treatment, defined as a normal or elevated TSH level, was observed in 94% of patients after oral administration and in 80% after intravenous administration; corresponding figures in the GD group were 68% and 65%. CONCLUSION: The causes of individual differences between targeted and therapeutically achieved doses remain undetermined. Variations in the bioavailability of radioiodide or other parameters affecting thyroid status may be involved, and further investigations are needed to clarify this.
Authors:
Peter Schneider; Johannes Biko; Heribert Hänscheid; Stephan Hilliger; Christos Koutsampelas; Michael Kranzfelder; Stephan Ladner; Christoph Reiners
Related Documents :
17978827 - Prediction of hypothyroidism after hemithyroidectomy: a biochemical and pathological an...
23504297 - Clinical characteristics of community-acquired acute pyelonephritis caused by esbl-prod...
20395857 - Parathyroidectomy improves functional capacity in "asymptomatic" older patients with pr...
24875277 - Preoperative study of the surface ecg for the prognosis of atrial fibrillation maze sur...
21609517 - Average 10.1-year follow-up of cementless total knee arthroplasty in patients with rheu...
15133467 - Optimum treatment of severe sepsis and septic shock: evidence in support of the recomme...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2005-03-10
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  32     ISSN:  1619-7070     ISO Abbreviation:  Eur. J. Nucl. Med. Mol. Imaging     Publication Date:  2005 Jul 
Date Detail:
Created Date:  2005-07-29     Completed Date:  2005-12-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  788-93     Citation Subset:  IM    
Affiliation:
Clinic for Nuclear Medicine, University of Würzburg, Josef-Schneider Strasse 2, 97080, Würzburg, Germany. schneider_P@nuklearmedizin.uni-wuerzburg.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Aged
Calibration
Female
Follow-Up Studies
Graves Disease / radionuclide imaging*,  radiotherapy*
Humans
Infusions, Intravenous
Iodine Radioisotopes / administration & dosage*,  diagnostic use*
Kinetics
Male
Middle Aged
Prospective Studies
Radiometry
Radiopharmaceuticals / administration & dosage,  diagnostic use
Reproducibility of Results
Thyroid Neoplasms / radionuclide imaging
Thyrotropin / metabolism
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Iodine Radioisotopes; 0/Radiopharmaceuticals; 9002-71-5/Thyrotropin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Apoptosis induced by oxalate in human renal tubular epithelial HK-2 cells.
Next Document:  Brain FDG PET study of normal aging in Japanese: effect of atrophy correction.